Data from Adrenomed’s AdrenOSS-2 trial with Adrecizumab in Septic Shock to be presented during e-ISICEM

DGAP-News: Adrenomed AG

/ Key word(s): Conference

14.09.2020 / 18:05

The issuer is solely responsible for the content of this announcement.

Data from Adrenomed’s AdrenOSS-2 trial with Adrecizumab in Septic Shock to be presented during e-ISICEM

Hennigsdorf/Berlin (Germany), September 14, 2020 – Adrenomed AG, the vascular integrity company, announced today that data from the AdrenOSS-2 Phase II clinical trial with Adrecizumab in septic shock (NCT03085758[1]) will be presented during the International Symposium on Intensive Care and Emergency Medicine, e-ISICEM, September 15-18, 2020.

Prof. Pierre-François Laterre, MD, Head of the medical-surgical intensive care unit at Saint Luc University Hospital at the Université Catholique de Louvain, Brussels (Belgium) and one of the principal investigators of the AdrenOSS-2 study, will present AdrenOSS-2 data in his talk “Adrecizumab in patients with high adrenomedullin levels” during the e-ISICEM sepsis session on Wednesday, September 16, 2020, available from 8:00 am CET.

AdrenOSS-2 evaluated the safety, tolerability and efficacy of Adrecizumab, a first-in-class monoclonal antibody targeting the vasoprotective peptide Adrenomedullin to restore and maintain vascular integrity in patients with early septic shock.

About Adrenomed

Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead product candidate Adrecizumab is a first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab has successfully completed a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 301 patients suffering from septic shock. For further information, please visit www.adrenomed.com and follow us on LinkedIn and Twitter.

Contact

Adrenomed AG
Frauke Hein, Ph.D. (Chief Business Officer)
phone: +49 (0)3302 2077814
fhein@adrenomed.com

Media Inquiries

MC Services AG
Eva Bauer / Julia von Hummel
phone: +49 (0)89 21022880
adrenomed@mc-services.eu

[1] clinicaltrials.gov/ct2/show/NCT03085758?term=NCT03085758&rank=1


14.09.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this